Table 3.

Sub-group analyses of 14-day and 30-day mortality following specific antibiotic therapies among CRKP-infected patients.

Mortality	No. of studies pooled	No. of patients	Odds Ratio (OR) (95% CI)	Heterogeneity of included studies
By 14-day
Monotherapy vs combination	8	935	1.42 (1.06–1.90); p = 0.020	I2 = 0.0%; p = 0.907
2-drug vs ≥ 3-drug combination	8	490	0.91 (0.59–1.41); p = 0.674	I2 = 0.0%; p = 0.844
Carbapenem-containing vs carbapenem-sparing	4	65	1.39 (0.31–6.16); p = 0.664	I2 = 0.0%; p = 0.700
Polymyxin-containing vs polymyxin-sparing	5	114	1.45 (0.50–4.16); p = 0.491	I2 = 0.0%; p = 0.531
Aminoglycoside-containing vs aminoglycoside-sparing	6	117	0.46 (0.17–1.24); p = 0.125	I2 = 0.0%; p = 0.504
Tigecycline-containing vs tigecycline-sparing	5	106	1.70 (0.60–4.78); p = 0.315	I2 = 0.0%; p = 0.890
By 28-day or 30-day
Monotherapy vs combination	14	763	1.54 (1.09–2.17); p = 0.015	I2 = 1.2%; p = 0.436
2-drug vs ≥ 3-drug combination	13	555	0.91 (0.59–1.42); p = 0.684	I2 = 9.2%; p = 0.353
Carbapenem-containing vs carbapenem-sparing	11	470	0.65 (0.37–1.12); p = 0.123	I2 = 14.2%; p = 0.309
Polymyxin-containing vs polymyxin-sparing	12	457	1.33 (0.64–2.75); p = 0.446	I2 = 53.8%; p = 0.014
Aminoglycoside-containing vs aminoglycoside-sparing	13	545	0.99 (0.58–1.67); p = 0.956	I2 = 27.0%; p = 0.172
Tigecycline-containing vs tigecycline-sparing	11	507	1.09 (0.48–2.45); p = 0.844	I2 = 56.1%; p = 0.012

The bold values represent the significant results.